SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), today announced a major expansion to its Connect 360 Autoimmune Program, including the introduction of Stelara ...

As a major component of the Connect 360 Autoimmune Program expansion, SmithRx will help employer clients and their employees adopt biosimilars, representing over 95% savings compared to Stelara ...

“Stelara has long been a cornerstone treatment for chronic inflammatory conditions, but with an annual cost up to $125,000 per patient, it’s a financial burden on members and payers alike,” said ...

"Stelara has long been a cornerstone treatment for chronic inflammatory conditions, but with an annual cost up to $125,000 per patient, it's a financial burden on members and payers alike," said ...

This is one of the first Stelara biosimilar market entrants in the country. Yesintek is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.

YESINTEK will be available in all the same formulations currently provided by Stelara. The available presentations are 45 mg/0.5 mL PFS, 90 mg/mL PFS, 45 mg/0.5 mL vial, and 130 mg/26 mL vial.

(Reuters) - Johnson & Johnson (NYSE:JNJ) sued Samsung (KS:005930) Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in ...

No significant differences were observed between Stelara and Entyvio in the 3-year risk for a composite of major adverse cardiovascular events. Stelara was linked with lower risk for all-cause ...